← Grant listing · GrantsDue Pro

Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)

National Institutes of Health · PAR-27-026 · Deadline: September 25, 2028

This listing sits under an agency-wide umbrella (CFDA 93.279, Drug Use and Addiction Research Programs — ~675 awards/yr across many separate competitions). Program-level statistics would describe the whole umbrella, not this competition, so we don't show them as if they were this opportunity's history. Any tool showing "award history" for this listing at the program level is describing the umbrella.

Listing summary

The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.

Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Health · official listing ↗

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.